|
Synonyms: CDX-0159
Compound class:
Antibody
Comment: Barzolvolimab (CDX-0159) is a clinical stage humanized anti-KIT IgG1 monoclonal antibody that was developed by Celldex Therapeutics (as claimed in their patent US10781267B2) [1]. CDX-0159 is a variant of CDX-0158 (a.k.a. KTN0158 [2]) that was re-engineered to improve its safety profile and increase its serum half-life. CDX-0158 was originally designed for potential to treat GIST and other KIT-dependent tumours. This original version of the antibody inhibits mutant and wild type KIT phosphorylation, reduces mast cell degranulation and mast cell numbers, and shrinks tumours in a preclinical canine model of spontaneous mast cell tumour development [2].
|
| No information available. |
Summary of Clinical Use  |
| CDX-0159 is being evaluated in early stage clinical trials for potential to block mast cell-mediated inflammation in certain skin conditions. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04944862 | A Study of CDX-0159 in Patients With Prurigo Nodularis | Phase 1 Interventional | Celldex Therapeutics | ||
| NCT04538794 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Phase 1 Interventional | Celldex Therapeutics | ||
| NCT04548869 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | Phase 1 Interventional | Celldex Therapeutics | ||
